Dr. Chapman Describes the Vemurafenib Clinical Trial

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Paul Chapman, MD from the Memorial Sloan-Kettering Cancer Center describes the vemurafenib clinical trial.

Dr. Chapman says the vemurafenib trial was a phase III randomized trial for patients with melanoma who had never had prior therapy whose tumors had a mutation in the BRAF gene. These patients were randomized to either receive the experimental drug, vemurafenib, or a standard chemotherapy. Patients were randomized 1:1 and initially no crossover was allowed. The results were that the patients on the vemurafenib arm showed a decreased risk of death of 63%, and as a result the early analysis that showed that decrease led to allowing the patients on the standard chemotherapy drug to crossover to the experimental arm.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content